Last updated: March 3, 2026
What is FACTIVE and Its Regulatory Status?
Factive (ciprofloxacin hydrochloride) is a broad-spectrum fluoroquinolone antibiotic approved for treating bacterial respiratory and urinary tract infections. It is marketed globally, with regulatory approvals from agencies such as the FDA (USA), EMA (Europe), and others. The drug is formulated primarily as oral tablets, with additional formulations in some markets.
How Does Excipient Selection Impact FACTIVE's Formulation and Efficacy?
Excipient choices influence FACTIVE’s stability, bioavailability, manufacturability, and patient adherence. Common excipients include disintegrants, binders, fillers, and lubricants.
| Excipient Category |
Typical Components |
Purpose |
Regulatory Considerations |
| Fillers and Binders |
Lactose, microcrystalline cellulose |
Provide bulk and cohesion |
Must be compatible with ciprofloxacin, minimize stability issues |
| Disintegrants |
Croscarmellose sodium |
Facilitate tablet disintegration |
Ensure rapid onset, stability-tested in ciprofloxacin formulations |
| Lubricants |
Magnesium stearate |
Ease manufacturing, prevent sticking |
Avoid excessive amounts that could affect dissolution |
| Coatings |
Hypromellose (HPMC), coating polymers |
Protect from moisture, mask taste |
Must not interfere with drug release, achieve uniform coating |
Optimizing Excipient Strategies
Advances in excipient technology enable formulation improvements:
- Use of moisture-resistant coatings to extend shelf life.
- Incorporation of disintegrants that shorten disintegration time.
- Selecting fillers that balance compressibility and stability.
Market Trends Impacting Excipient Choices
Global brands seek excipients aligned with:
- Regulatory approval for human use in multiple regions.
- Supply chain stability to mitigate shortages.
- Patient safety by avoiding allergens such as lactose in certain formulations.
- Cost constraints, favoring excipients that optimize manufacturing costs without compromising quality.
Commercial Opportunities in Excipient Development for FACTIVE
- Formulation Innovation: Developing modified-release capsules or tablets that improve compliance, potentially commanding premium pricing.
- Excipient Novelty: Introducing proprietary excipients that enhance stability or reduce manufacturing costs.
- Quality-by-Design (QbD) Approaches: Refining excipient profiles for robust processes that reduce batch failure risk.
- Supply Chain Security: Collaborating with excipient suppliers for consistent, high-quality raw materials, reducing risk of shortages.
- Regulatory Advantage: Achieving excipient ingredient approvals that simplify registration and market entry.
Differential Strategies for Market Segments
- Developed markets: Focus on excipient safety, tolerability, and innovative formulations to differentiate.
- Emerging markets: Prioritize cost-effective excipients with broad regulatory acceptance.
Intellectual Property and Patent Landscape
Patents covering excipient combinations or proprietary formulations of FACTIVE can provide exclusivity. Companies investing in new excipient systems may secure:
- Formulation patents.
- Process patents regarding excipient blending or coating processes.
- Use patents for extended-release or combination formulations.
Challenges and Risks
- Regulatory hurdles: Novel excipients require extensive testing and approval.
- Supply limitations: Dependence on specific excipient suppliers can delay manufacturing.
- Patent expirations: Open market opportunities as patents lapse, especially for older formulations.
- Formulation complexity: Balancing stability, bioavailability, and manufacturability remains challenging.
Key Takeaways
- Excipient selection is critical for FACTIVE's stability, bioavailability, and patient compliance.
- Innovations in excipient technology can lead to differentiated formulations, enabling premium pricing and market share expansion.
- Supply chain stability, regulatory approval, and cost considerations drive excipient strategies.
- Patent protections for unique formulations or excipient combinations can provide competitive advantages.
FAQs
1. What excipients are typically used in FACTIVE formulations?
Lactose or microcrystalline cellulose as fillers, croscarmellose sodium as a disintegrant, magnesium stearate as a lubricant, and hypromellose-based coatings are common.
2. How can excipient choices improve FACTIVE’s bioavailability?
Selecting disintegrants that promote rapid tablet disintegration and coatings that protect the drug from moisture enhances absorption and reduces variability.
3. Are there opportunities for new excipients in FACTIVE formulations?
Yes. Innovative excipients that improve stability or release profiles offer differentiation. Proprietary excipients can also provide patent protection.
4. What regulatory challenges exist for excipient innovations?
New excipients undergo rigorous safety evaluations and require approval from agencies like the FDA or EMA, which can delay development timelines.
5. How does the patent landscape influence excipient strategies?
Patent protection on specific excipient combinations or formulations creates barriers for competitors. Expiry opens opportunities for generic development.
References
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products and Biological Products.
[2] European Medicines Agency. (2021). Guidelines on excipient qualification and safety for medicinal products for human use.
[3] Arora, S., & Sethi, V. (2020). Advances in pharmaceutical excipients: An overview. Journal of Drug Delivery Science and Technology, 56, 101627.
